A study comparing rivaroxaban or warfarin versus low molecular weight heparin (LMWH) for the treatment of treatment of venous-thromboembolism in cancer patients

Trial Profile

A study comparing rivaroxaban or warfarin versus low molecular weight heparin (LMWH) for the treatment of treatment of venous-thromboembolism in cancer patients

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Sponsors Janssen
  • Most Recent Events

    • 18 Dec 2015 New trial record
    • 07 Dec 2015 According to a Janssen Pharmaceuticals media release, results from this trial were presented at the 2015 American Society of Hematology (ASH) Annual Meeting.
    • 07 Dec 2015 Results were published in a Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top